Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Hardman & Co Q&A on Oakley Capital Investments (OCI): 2022 Results: EBITDA Growth Drives NAV Appreciation
Hardman & Co Q&A on Oakley Capital Investments (OCI): 2022 Results: EBITDA Growth Drives NAV Appreciation
Hardman & Co Q&A on Oakley Capital Investments (OCI): 2022 Results: EBITDA Growth Drives NAV Appreciation
eqs_en 
0 31.03.23
Portfolio company Harpoon Therapeutics announces closing of $25 million private placement
Portfolio company Harpoon Therapeutics announces closing of $25 million private placement
Portfolio company Harpoon Therapeutics announces closing of $25 million private placement
eqs_en 
0 28.03.23
Hardman & Co Research on City Of London Investment Group (CLIG): Solid results in volatile markets
Hardman & Co Research on City Of London Investment Group (CLIG): Solid results in volatile markets
Hardman & Co Research on City Of London Investment Group (CLIG): Solid results in volatile markets
eqs_en 
0 22.03.23
Unaudited NAV for February 2023
Unaudited NAV for February 2023
Unaudited NAV for February 2023
eqs_en 
0 16.03.23
Hardman & Co Research on Oakley Capital Investments Ltd (OCI): 2022: NAV returns driven by EBITDA growth
Hardman & Co Research on Oakley Capital Investments Ltd (OCI): 2022: NAV returns driven by EBITDA growth
Hardman & Co Research on Oakley Capital Investments Ltd (OCI): 2022: NAV returns driven by EBITDA growth
eqs_en 
0 15.03.23
Purplebricks Group Plc: Directorate change
Purplebricks Group Plc: Directorate change
Purplebricks Group Plc: Directorate change
eqs_en 
0 07.03.23
Form 8.3 - Maitland Institutional Services Limited: Re Purple Bricks Group plc
Form 8.3 - Maitland Institutional Services Limited: Re Purple Bricks Group plc
Form 8.3 - Maitland Institutional Services Limited: Re Purple Bricks Group plc
eqs_en 
0 02.03.23
Purplebricks Group Plc: Strategic Review Update – Launch of Formal Sale Process under the Takeover Code
Purplebricks Group Plc: Strategic Review Update – Launch of Formal Sale Process under the Takeover Code
Purplebricks Group Plc: Strategic Review Update – Launch of Formal Sale Process under the Takeover Code
eqs_en 
0 01.03.23
Form 8.3 - Maitland Institutional Services Limited: Re Purple Bricks Group PLC
Form 8.3 - Maitland Institutional Services Limited: Re Purple Bricks Group PLC
Form 8.3 - Maitland Institutional Services Limited: Re Purple Bricks Group PLC
eqs_en 
0 27.02.23
Form 8.3 - Maitland Institutional Services Limited: Re Purple Bricks Group plc - Replacement Disclosure
Form 8.3 - Maitland Institutional Services Limited: Re Purple Bricks Group plc - Replacement Disclosure
Form 8.3 - Maitland Institutional Services Limited: Re Purple Bricks Group plc - Replacement Disclosure
eqs_en 
0 20.02.23
Form 8.3 - Maitland Institutional Services Limited: Form 8.3 - OPD - Purple Bricks Group PLC
Form 8.3 - Maitland Institutional Services Limited: Form 8.3 - OPD - Purple Bricks Group PLC
Form 8.3 - Maitland Institutional Services Limited: Form 8.3 - OPD - Purple Bricks Group PLC
eqs_en 
0 17.02.23
Purplebricks Group Plc: Trading update and Launch of Strategic Review
Purplebricks Group Plc: Trading update and Launch of Strategic Review
Purplebricks Group Plc: Trading update and Launch of Strategic Review
eqs_en 
0 17.02.23
Portfolio company Disc Medicine announces $62.5 million financing
Portfolio company Disc Medicine announces $62.5 million financing
Portfolio company Disc Medicine announces $62.5 million financing
eqs_en 
0 14.02.23
Unaudited NAV for January 2023
Unaudited NAV for January 2023
Unaudited NAV for January 2023
eqs_en 
0 06.02.23
Unaudited NAV for December 2022
Unaudited NAV for December 2022
Unaudited NAV for December 2022
eqs_en 
0 30.01.23
Board Change
Board Change
Board Change
eqs_en 
0 26.01.23
Hardman & Co Research on City of London Investment Group: Swings and roundabouts
Hardman & Co Research on City of London Investment Group: Swings and roundabouts
Hardman & Co Research on City of London Investment Group: Swings and roundabouts
eqs_en 
0 25.01.23
Hardman & Co Q&A on Oakley Capital Investments Ltd (OCI): High-growth drivers in 2023
Hardman & Co Q&A on Oakley Capital Investments Ltd (OCI): High-growth drivers in 2023
Hardman & Co Q&A on Oakley Capital Investments Ltd (OCI): High-growth drivers in 2023
eqs_en 
0 18.01.23
Portfolio company Twelve Bio to be acquired alongside $85 million financing of Ensoma
Portfolio company Twelve Bio to be acquired alongside $85 million financing of Ensoma
Portfolio company Twelve Bio to be acquired alongside $85 million financing of Ensoma
eqs_en 
0 05.01.23
Portfolio Company Disc Medicine Completes Merger with Gemini Therapeutics
Portfolio Company Disc Medicine Completes Merger with Gemini Therapeutics
Portfolio Company Disc Medicine Completes Merger with Gemini Therapeutics
eqs_en 
0 30.12.22
Unaudited NAV for November 2022
Unaudited NAV for November 2022
Unaudited NAV for November 2022
eqs_en 
0 12.12.22
Arix to Present at Mello Investment Trusts & Funds
Arix to Present at Mello Investment Trusts & Funds
Arix to Present at Mello Investment Trusts & Funds
eqs_en 
0 06.12.22
Hardman & Co Research on Oakley Capital Investments Ltd (OCI): Evolution of the high-growth drivers in 2023
Hardman & Co Research on Oakley Capital Investments Ltd (OCI): Evolution of the high-growth drivers in 2023
Hardman & Co Research on Oakley Capital Investments Ltd (OCI): Evolution of the high-growth drivers in 2023
eqs_en 
0 29.11.22
Hardman & Co Research on City Of London Investment Group: (CLIG) Solid profits in tough markets
Hardman & Co Research on City Of London Investment Group: (CLIG) Solid profits in tough markets
Hardman & Co Research on City Of London Investment Group: (CLIG) Solid profits in tough markets
eqs_en 
0 15.11.22
Unaudited NAV for October 2022
Unaudited NAV for October 2022
Unaudited NAV for October 2022
eqs_en 
0 09.11.22